A multicentre phase III study comparing efficacy and safety of novel extended-release versus conventional formulation of dydrogesterone in Indian patients with endometriosis

T. Sasikala; Shikha Kushwaha; Mukta Agarwal; Vandana Jain; Deepti Bawa; Suchitra Narayan; Pavankumar Daultani; Ashok Jaiswal; Monika Chinda; Anit Singh

doi:10.18203/2320-1770.ijrcog20241298

Authors

T. Sasikala Department of Gynaecology, Government Medical College and Government General Hospital (old RIMSSGH), Srikakulam, Andhra Pradesh, India
Shikha Kushwaha Department of Obstetrics and Gynecology, Prakhar Hospital Pvt Ltd, Kanpur, Uttar Pradesh, India
Mukta Agarwal Department of Obstetrics and Gynecology, All India Institute of Medical Science, Phulwari, Patna, Bihar, India
Vandana Jain Department of Gynecology, Unity Hospital, Ahmedabad, Gujarat, India
Deepti Bawa Department of Gynecology, Citizen Hospital, Bangalore, Karnataka, India
Suchitra Narayan Jawahar Lal Nehru Medical College, Ajmer, Rajasthan, India
Pavankumar Daultani New Product Development, Zydus Healthcare Limited, Ahmedabad, Gujarat, India
Ashok Jaiswal Medical Affairs, Zydus Healthcare Limited, Mumbai, Maharashtra, India
Monika Chinda Medical Affairs, Zydus Healthcare Limited, Mumbai, Maharashtra, India
Anit Singh Clinical Research Network, Noida, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20241298

Keywords:

Dydrogesterone, Endometriosis, Extended-release, Pelvic pain, Progesterone

Abstract

Background: The aim of the study was to compare the efficacy and safety of novel once-daily extended-release (ER) dydrogesterone 20 mg versus conventional twice-daily dydrogesterone 10 mg in Indian patients with endometriosis.

Methods: A phase III prospective, randomized, double-blind, single-dummy, two-arm, active-controlled, parallel, multicenter study was performed in six gynecology centers across India. The patients of 18 to 45 years of age with a confirmed diagnosis of endometriosis on ultrasonography (USG) and having endometriosis-associated pelvic pain score (EAPP) of at least 30 mm on a 100 mm visual analog scale (VAS) were randomly assigned to a 1:1 ratio to either once-daily dydrogesterone ER 20 mg or twice-daily dydrogesterone 10 mg arms for a treatment period of 90 days. The primary outcome was a change from baseline in EAPP score at the end of the treatment.

Results: A total of 228 patients with a mean age of 31.8±6.9 years were enrolled in the study. At day 90, both the treatment arms showed a significant reduction (p<0.05) in EAPP score from baseline (i.e. -34.2±15.3 mm and -33.1±14.8 mm in once daily dydrogesterone ER and twice daily dydrogesterone 10 mg, respectively), with no significant difference between the two arms (p=0.53). With both formulations, patients experienced a significant reduction in the size of endometrioma, serum vascular endothelial growth factors (VEGF) levels, use of rescue analgesics, and significant improvement in the health-related quality-of-life parameters. A favorable safety profile of dydrogesterone was confirmed, and no significant safety concerns were reported during the study.

Conclusions: Once daily dydrogesterone ER 20 mg and twice daily dydrogesterone 10 mg demonstrated a significant and similar reduction in EAPP and all other secondary parameters along with marked improvements in parameters related to quality of life.

Metrics

Metrics Loading ...

References

Dunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, Bie BD, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400-12.

Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D, D’Hooghe T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril. 2009;92(1):68-74.

Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Marshall LM, Hunter DJ. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol. 2004;160:784-96.

Gajbhiye RK, Montgomery G, Pai MV, Phukan P, Shekhar S, Padte K, et al. Protocol for a case-control study investigating the clinical phenotypes and genetic regulation of endometriosis in Indian women: the ECGRI study. BMJ Open. 2021;11:e050844.

La Rosa VL, De Franciscis P, Barra F, Schiattarella A, Török P, Shah M, et al. Quality of life in women with endometriosis: a narrative overview. Minerva Med. 2020;111(1):68-78.

La Rosa VL, De Franciscis P, Barra F, Schiattarella A, Tropea A, Tesarik J, et al. Sexuality in women with endometriosis: a critical narrative review. Minerva Med. 2020;111(1):79-89.

National Guideline Alliance (UK). Endometriosis: diagnosis and management. London: National Institute for Health and Care Excellence (NICE). 2017.

Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C, et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019;38(2):249-59.

Rižner TL, Brožič P, Doucette C, Turek-Etienne T, Muller-Vieira U, Sonneveld E, et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011;76(6):607-15.

Johnston WIH. Dydrogesterone and endometriosis. Br J Obstetr Gynaecol. 1976;83(1):77-80.

Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C. Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. Health Qual Life Outcomes. 2010;8:138.

Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400-12.

Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014;101:927-35.

Hodgson RM, Lee HL, Wang R, Mol BW, Johnson N. Interventions for endometriosis-related infertility: a systematic review and network metaanalysis. Fertil Steril. 2020;113:374-82.

Harada T, Momoeda M, Taketani Y, Hoshiai H, Terawaka N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo controlled, double-blind, randomized trial. Fertil Steril. 2008;90:1583-8.

Johnson NP, Hummelshoj L, World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod. 2013;28:1552-68.

Bedaiwy MA, Allaire C, Alfaraj S. Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertil Steril. 2017;107:537-48.

Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107:533-6.

Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2018;5:CD001019.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453-7.

Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev. 2003;2003:CD001297.

Schweppe K-W. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas 2009;65(1):S23-7.

Johnston WI. Dydrogesterone and endometriosis. Br J Obstet Gynaecol. 1976;83:77-80.

Walker SM. The treatment of endometriosis with dydrogesterone. Br J Clin Pract. 1983;24:40-6.

Trivedi P, Selvaraj K, Mahapatra PD, Srivastava S, Malik S. Effective postlaparoscopic treatment of endometriosis with dydrogesterone. Gynecol Endocrinol 2007;23(1):73-6.